Nibras Mohammed Sahi | Drug Delivery Systems | Women Researcher Award

Posted on by sciencefather

Nibras Mohammed Sahi | Drug Delivery Systems | Women Researcher Award

Assist. Prof. Dr. Nibras Mohammed Sahi, Ministry of Higher Education and Scientific Research, University of Babylon, Iraq

Dr. Nebras Mohammed Sahi 🦋, an Assistant Professor at the University of Babylon, specializes in entomology and plant extracts 🌿. Her research explores insect-derived products and medicinal plant applications in anticancer and antibacterial treatments 🧪. She has contributed to high-impact journals 📄 indexed in SCI and Scopus. Dr. Sahi prepared the propolis and Alhagi maurorum extract used in her latest research. Her work advances medicine, agriculture, and sustainability 🌍. With a citation index of 3, she actively collaborates on innovative biological studies. 💡🔬

Publication Profile

orcid

Professional Background

Dr. Nibras Mohammed Sahi 🦋, an Assistant Professor, specializes in entomology and plant extracts, focusing on the study of insects and their beneficial products. Her research explores the diverse applications of insect-derived compounds in medicine 💊, agriculture 🌱, and sustainability 🌍. Through collaborations with universities and research institutions, she investigates innovative ways to harness the potential of insects for ecological and economic benefits. Driven by a passion for scientific discovery 🔬, Dr. Sahi’s work contributes to advancements in bio-based solutions, aiming to enhance environmental conservation and agricultural productivity while promoting sustainable development.

Ongoing Research

Dr. Nibras Mohammed Sahi 🦋 is actively engaged in research on insect-derived products and plant extracts, with a particular focus on propolis 🐝 and Alhagi maurorum 🌿 for cancer 🧬 and antibacterial 🦠 applications. Her studies explore the therapeutic potential of these natural compounds, aiming to develop innovative solutions in medicine 💊 and biotechnology. While her work aligns with prestigious award categories, highlighting specific project funding 💰, collaborations 🤝, or research grants would further strengthen her academic profile. Through her dedication to scientific discovery 🔬, Dr. Sahi contributes to advancements in natural product research and sustainable healthcare solutions.

Professional Memberships

Dr. Nibras Mohammed Sahi 🦋 has not listed any editorial appointments, active collaborations, or professional memberships. However, participation in scientific societies 🏛️, international conferences 🎤, or editorial boards 📑 would significantly enhance her academic profile. Engaging in peer-reviewed journals 📚, contributing to scientific committees 🏅, or collaborating on global research initiatives 🌍 would further establish her influence in the field of entomology and natural product research. Highlighting such professional engagements would strengthen her candidacy, showcasing her dedication to advancing scientific knowledge 🔬 and fostering collaborations that drive innovation in medicine 💊, agriculture 🌱, and sustainability 🌿.

Research Focus

Assist. Prof. Dr. Nibras Mohammed Sahi’s research primarily focuses on microbiology 🦠, antibiotic resistance 💊, and bioactive compounds 🌱. His studies encompass pathogenic bacteria identification 🧫, antimicrobial activity testing 🧪, and molecular genetics 🧬 related to infectious diseases. He has extensively investigated natural plant extracts 🌿 and fungal metabolites 🍄 for their antibacterial and antifungal properties, along with genetic factors in diseases 🧑‍⚕️ like hepatitis B and colorectal cancer. His work also extends to insecticidal bioactive compounds 🪲 and their effects. His research contributes significantly to public health 🏥, pharmacology 💉, and molecular diagnostics 🔬.

Publication Top Notes

Molecular & Antibiotic Sensitivity Pattern Study of Acute Otitis Media, Tonsillitis & Periodontitis among Different Ages of Patients of Al-Hashmia General Hospital, Primary Care Centers & Private Clinic in Babylon Province

Analysis of Methanolic extract of Secondary Metabolites Released by Candida glabratus using GC-MS and Evaluation of Its Antimicrobial Activity

Detection of Bioactive Compounds of Raphanus sativus Using GC-MS and FT-IR Technical Analysis and Determination of its Anti-Bacterial and Anti-Fungal Activity.

Isolation and Identification of Some Pathogenic Bacteria from Otitis Media in Babylon Governorate

Antimicrobial Effect of the Crude Phenolic, Alkaloid and Terpenoid Compounds Extracts of Myrtus Communis L. against Human Gram-Negative Pathogenic Bacteria

Antimicrobial Effect of the Crude Phenolic, Alkaloid and Terpenoid Compounds Extracts of Myrtus Communis L. against Human Gram-Negative Pathogenic Bacteria

Liangliang Dai | Drug Delivery Systems | Best Researcher Award

Posted on by sciencefather

Liangliang Dai | Drug Delivery Systems | Best Researcher Award

Prof  Liangliang Dai, Northwestern Polytechnical University, China

Prof. Liangliang Dai Associate Professor & Assistant Dean, Institute of Medical Research, Northwestern Polytechnical University. With a PhD and MD in Biomedical Engineering and Biology from Chongqing University under Prof. Kaiyong Cai, Prof. Dai’s research focuses on nanomaterials, drug delivery systems, nanosystems, tumor immunotherapy, and antimetabolic therapy. He has led multiple national and provincial research projects and published in top journals like Nature Communications and Advanced Functional Materials. His innovative work bridges nanotechnology and cancer therapy, advancing biomedical science. 🔬🌿

Publication Profile

orcid

Education Background

Prof. Liangliang Dai holds a Ph.D. in Biomedical Engineering 🎓 from the Ministry of Education College of Bioengineering at Chongqing University, where he conducted advanced research under the mentorship of Prof. Kaiyong Cai. His academic journey also includes an MD in Biology 🧬 from the same institution, further solidifying his expertise in bioengineering and biomedical sciences. Guided by Prof. Cai, his studies focused on cutting-edge innovations in the field. With a strong foundation in interdisciplinary research, Prof. Dai continues to contribute to scientific advancements in biomedical engineering and biology, shaping the future of healthcare and biotechnology 🔬.

Hosted Research Project

Prof. Liangliang Dai has led several prestigious research projects 🔬, contributing significantly to biomedical engineering. He has been awarded funding from the National Natural Science Foundation of China 🏅 for multiple projects (52373157, 52003223) and has received the National Science Foundation for Distinguished Young Scholars of Shaanxi Province (S2025-JC-JQ-0228). Additionally, he has played a key role in the Key R&D Programs of Shaanxi Province (2024SF2-GJHX-26, 2022SF-012) and secured support from the Natural Science Foundation of Shaanxi Province (2019JQ-347) and the Young Talent Fund of University Association for Science and Technology (20200302) 🌍.

Research Contributions

Prof. Liangliang Dai has secured multiple prestigious research grants 🏅, including funding from the National Natural Science Foundation of China and the Key R&D Program of Shaanxi Province. His research focuses on advanced drug delivery systems 💊, tumor immunotherapy 🧬, and biomedical nanotechnology 🔬, making significant contributions to the medical research community. These competitive grants reflect his expertise and the high regard for his work in the scientific field. Through pioneering innovations, Prof. Dai continues to push the boundaries of biomedical engineering, striving for breakthroughs that enhance healthcare and therapeutic solutions globally 🌍.

Global Recognition 

Prof. Liangliang Dai is a globally recognized researcher 🌍, collaborating with renowned scientists to develop innovative therapeutic strategies 🔬. His groundbreaking work in cancer therapy 🧬 and nanomaterial-based drug delivery 💊 is paving the way for more effective medical treatments. Beyond securing prestigious grants and publishing impactful research, his contributions hold practical significance in biomedical applications, transforming healthcare solutions. With a commitment to advancing science, Prof. Dai’s influence continues to grow, driving innovation and shaping the future of medicine through cutting-edge technologies and interdisciplinary collaborations 🤝.

Innovative Research

Prof. Liangliang Dai’s research is highly interdisciplinary 🔬, blending nanotechnology, immunotherapy, and bioengineering to advance medical science. His groundbreaking work on multifunctional metal-organic frameworks 🏗️, light-activatable antibiosis for infected bone repair 🦴, and tumor microenvironment modulation 🧬 showcases his pioneering role in translational medicine. By enhancing cancer treatment strategies 🎗️ and optimizing drug delivery systems 💊, his studies have a direct impact on healthcare. Through cutting-edge innovations, Prof. Dai is shaping the future of biomedical science, driving transformative solutions that improve patient outcomes and therapeutic effectiveness worldwide 🌍.

Research Focus

Liangliang Dai’s research primarily focuses on nanotechnology and biomedical engineering 🧪🔬, with a particular emphasis on nanosystems for drug delivery, tumor therapy, and environmental applications. His work explores nanoparticles, metal-organic frameworks (MOFs), and photo-responsive materials to develop advanced cancer treatments 🎗️, chemodynamic therapy ⚛️, immune modulation 🛡️, and antimicrobial strategies 🦠. Dai also investigates water purification 💧 and biofilm control to tackle antibiotic resistance. His research bridges materials science 🏗️ and biomedicine to create multifunctional therapeutic nanosystems, advancing precision medicine 🧬 and environmental health 🌍.

Publication Top Notes

Nanosilver-Induced Pseudo Cuproptosis of Potentially Pathogenic Bacteria during the Storage of Ozone-Treated Wastewater

MMP-2/GSH-responsive nanobomb for tumor chemo-immunotherapy with hierarchical delivery and TAMs re-education by regulating hbegf-activated ERK/MAPK signal pathway

An Adjuvant Micelle-Based Multifunctional Nanosystem for Tumor Immunotherapy by Remodeling Three Types of Immunosuppressive Cells.

Multifunctional Fe-based coordination polymer nano-bomb modified with β-lapachone and CaO<sub>2</sub> for targeted tumor dual chemodynamic therapy with enhanced ferroptosis and H<sub>2</sub>O<sub>2</sub> self-supply.

A Photo‐Therapeutic Nanocomposite with Bio‐Responsive Oxygen Self‐Supplying Combats Biofilm Infections and Inflammation from Drug‐Resistant Bacteria

Detachable MOF-Based Core/Shell Nanoreactor for Cancer Dual-Starvation Therapy With Reversing Glucose and Glutamine Metabolisms.

Engineered drug delivery nanosystems for tumor microenvironment normalization therapy

Cascade amplification of tumor chemodynamic therapy and starvation with re-educated TAMs via Fe-MOF based functional nanosystem

Prof.Aleksandr Urakov|Drug Repurposing | Best Researcher Award

Posted on by sciencefather

Prof.Aleksandr Urakov, Drug Repurposing ,Best Researcher Award

Prof.Aleksandr Urakov atIzhevsk State Medical Academy,Russia

PROFILE  

scopus

Orcid

Academic Leadership 🏫

Professor Aleksandr Urakov serves as the head of the Department of General and Clinical Pharmacology at Izhevsk State Medical Academy. His leadership has been instrumental in shaping the department into a center of excellence in pharmacological research and education.

Innovative Contributions 🧠

As an inventor, Professor Urakov holds over 270 patents and has published more than 200 scientific articles . His research in temperature pharmacology and drug repurposing  has led to significant advancements, including the development of the floating tablet and warm alkaline hydrogen peroxide solutions .

Recognition and Honors 🎖️

For his remarkable contributions, Professor Urakov has been awarded the Order of the Badge of Honor and holds the prestigious title of Honored Inventor of the Russian Federation . His work continues to influence and inspire the medical community globally.

Research and Innovations🔬 :

Professor Urakov invented the floating tablet and discovered warm alkaline hydrogen peroxide solutions (WAHPSs), which include new drug subgroups like bruise bleaches, pus-dissolving drugs (pyolytics), and oxygen-producing antihypoxants. These innovations offer alternatives to ECMO for hypoxemia in COVID-19 asphyxia.

🎓Publication 

Comment: Balanced Salt Solutions for Critically Ill Patients: Nonplused and Back to Basics

Thermal imaging of local skin temperature as part of quality and safety assessment of injectable drugs

    • Authors :Urakov, A., Urakova, N., Samorodov, A., … Suntsova, D., Muhutdinov, N..
    • Journal   :Heliyon
    • Year       : 2024

Understanding burn injuries in children – A step toward prevention and prompt first aid

  • Authors  :Urakov, A.L., Suntsova, D.O., Yagudin, I.I.
  • Journal    :Burns
  • Year         :  2023

ASSESSMENT OF FETAL RESISTANCE TO HYPOXIA USING THE STANGE TEST AS AN ADJUNCT TO APGAR SCALE ASSESSMENT OF NEONATAL HEALTH STATUS

  • Authors  :Shabanov, P.D., Urakov, A.L., Urakova, N.A.
  • Journal   :Medicinskij Akademiceskij Zurnal,
  • Year        :   2023

Prospects for the pharmacological validation of the use of platelets as a “peripheral model” of neurons

Assoc Prof Dr.Guanyu Chen|Drug Delivery Systems | Best Researcher Award

Posted on by sciencefather

Assoc Prof Dr.Guanyu Chen, Drug Delivery Systems,Best Researcher Award

Assoc Prof Dr.Guanyu Chen, at Sun Yat-Sen University School of Pharmaceutical Sciences Shenzhen,China

PROFILE  

scopus

🧪 Research Focus :

Associate Prof. Guanyu Chen is an expert in Drug Delivery and Immunochemotherapy at the School of Pharmaceutical Sciences, Sun Yat-sen University.

🎓 Education and Professional Experience :

He earned his Bachelor’s (2005-2008), Master’s (2009-2012), and PhD (2012-2016) degrees from the University of Auckland, New Zealand. Following his PhD, he worked as a Postdoctoral Fellow at the same university from 2017 to 2019. During this time, he also served as a Research Assistant at Ancare Scientific Ltd, Douglas Ltd, Alleva Animal Health Ltd, and Kimberly Clack Ltd. In 2019, he joined Sun Yat-sen University, China, as an Associate Professor.

💰 Research Funding :

Prof. Chen has received significant funding for his research, including the National Natural Science Foundation of China in 2022 (82273871), the Guangdong Basic and Applied Basic Research Foundation in 2021 (2021A1515110006), the Shenzhen Science and Technology Program in 2020 (GXWD20201231165807008), the 67th Batch Postdoc Research Foundation of China in 2019 (2020M673030), and the Kimberly Clarks Pharmaceutics Research Fund, USA in 2016 (32715.001).

🏅 Patents and Awards :

His achievements include two national invention patents and several prestigious awards: Overseas Senior Talent of Shenzhen, Recruiting Outstanding Overseas Talent of Guangdong, Maurice and Phyllis Paykel Research Award, Academic Career Exploration Scholarship, Edna and Denis Moloney Scholarship, FMHS-PGSA Award from the University of Auckland, Elite Editing Thesis Write-up Scholarship from Australia, and The University of Auckland Partnership Appeal Award.

📚 Editorial Roles :

Prof. Chen contributes to the academic community as a Youth Editorial Board Member for Acta Materia Medica and the Journal of Drug Delivery and Translational Research. He also serves as a Guest Editor for the Journal of Current Drug Delivery and Pharmaceutics.

🔍 Conclusion

Associate Prof. Guanyu Chen stands out as a leading researcher in drug delivery and immunochemotherapy, with a robust academic background and extensive experience. His significant contributions to the field are supported by notable research funding and a series of prestigious awards. As a dedicated academic and editorial contributor, Prof. Chen continues to advance pharmaceutical sciences through his research, mentorship, and publication efforts.

🎓Publication 

The scaffold protein AXIN1: gene ontology, signal network, and physiological function

Minocycline prevents photoreceptor degeneration in Retinitis pigmentosa through modulating mitochondrial homeostasis

Cryo-Milled β-Glucan Nanoparticles for Oral Drug Delivery

  • Authors  :Chen, G., Liu, Y., Svirskis, D., … Lu, W., Wen, J.
  • Journal    :Pharmaceutics
  • Year         :  2024

Fish oil-based microemulsion can efficiently deliver oral peptide blocking PD-1/PD-L1 and simultaneously induce ferroptosis for cancer immunotherapy

Development of a novel peptide targeting GPR81 to suppress adipocyte-mediated tumor progression

  • Authors  :Chen, S., Zhou, X., Li, W., … Liu, J., Gao, Y.
  • Journal   :Biochemical Pharmacology
  • Year        :  2023